Compare OGE & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGE | HALO |
|---|---|---|
| Founded | 1902 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.8B |
| IPO Year | N/A | N/A |
| Metric | OGE | HALO |
|---|---|---|
| Price | $44.34 | $80.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $47.11 | ★ $76.42 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 02-18-2026 | 02-18-2026 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | 29.01 | ★ 56.68 |
| EPS | 2.49 | ★ 4.74 |
| Revenue | ★ $3,294,800,000.00 | $1,242,852,000.00 |
| Revenue This Year | $6.45 | $34.54 |
| Revenue Next Year | $4.37 | $26.28 |
| P/E Ratio | $17.65 | ★ $17.15 |
| Revenue Growth | 18.03 | ★ 31.19 |
| 52 Week Low | $40.80 | $47.50 |
| 52 Week High | $47.33 | $81.36 |
| Indicator | OGE | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 72.30 |
| Support Level | $42.93 | $71.23 |
| Resistance Level | $44.54 | $74.48 |
| Average True Range (ATR) | 0.74 | 2.47 |
| MACD | 0.11 | 0.88 |
| Stochastic Oscillator | 91.33 | 89.45 |
OGE Energy is a holding company for Oklahoma Gas & Electric, a regulated utility with electricity generation, transmission, and distribution service for 900,000 customers in Oklahoma and western Arkansas. In December 2021, OGE divested its 25.5% stake in Enable Midstream Partners, an oil and gas services company it created in 2013 through a unit exchange merger with Energy Transfer. OGE sold its 95.4 million limited partner units of Energy Transfer throughout 2022. OGE sold its retail gas business in 1928 and no longer has any gas operations.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.